By Ismail Shakil May 2 (Reuters) – Pharmaceutical company Danco Laboratories filed an application with the U.S. Supreme Court on Saturday seeking a stay of an appeals court ruling that temporarily blocks the abortion drug mifepristone from being dispensed through the mail. The appeals court ruling was issued unanimously by a conservative three-judge panel on Friday, significantly curtailing access to the drug nationwide and particularly in states that have banned abortion. The temporary decision was made in a case brought by Republican-led state of Louisiana claiming the FDA in adopting a 2023 rule – which allows mifepristone to be dispensed through the mail – had ignored the risks of serious adverse events posed by the drug, including sepsis and hemorrhaging.
Latest development
Media Coverage · May 2, 2026
The court issued an order.
newspaper Read articleBy Ismail Shakil May 2 (Reuters) – Pharmaceutical company Danco Laboratories filed an application with the U.S. Supreme Court on Saturday seeking a stay of an appeals court ruling that temporarily blocks the abortion drug mifepristone from being dispensed through the mail. The appeals court ruling was issued unanimously by a conservative three-judge panel on Friday, significantly curtailing access to the drug nationwide and particularly in states that have banned abortion. The temporary decision
Open original open_in_newJuryvine summaries are generated from court records. Expand "Source" on any row to see the underlying filing.
The court issued an order.
By Ismail Shakil May 2 (Reuters) – Pharmaceutical company Danco Laboratories filed an application with the U.S. Supreme Court on Saturday seeking a stay of an appeals court ruling that …
Sources tracked
1 outlet · 1 article
Timeline events
1 record on file
Last updated
2 days, 7 hours ago
Juryvine aggregates docket entries from PACER/CourtListener, press coverage, and GDELT signals. Ingestion timestamps do not appear in the What Changed feed — that reflects real court activity only.